

References

E-5

1. Burri S, Gondi V, et al. The evolving role of tumor treating fields in managing glioblastoma: Guide for oncologists. *Am J Clin Oncol*. 2018;41:191-196.
2. Kinzel A, Abbroggi M, Varshaver M, Kirson E. Tumor treating fields for glioblastoma treatment: Patient satisfaction and compliance with the second-generation Optune® system. *Clin Med Insights Oncol*. 2019;13:1-7.
3. Trusheim J, Dunbar E, Battiste J, et al. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. *CNS Oncol*. 2017;6(1):29–43.
4. Hayes, Inc. Hayes Health Technology Assessment. *Tumor Treating Fields (Optune) for Treatment of Glioblastoma*. Landsdale, PA: Hayes, Inc.; 12/27/2019.
5. Benson L. Tumor treating fields technology: Alternating electric field therapy for the treatment of solid tumors. *Semin Oncol*. 2018;34(2):137-150.
6. Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumor treating field in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable pleural mesothelioma (STELLAR): A multicenter, single-arm phase 2 trial. *Lancet Oncol*. 2019;20:1702-99.
7. Wang Y, Pandey M, Ballo M. Integration of tumor treating fields into the multidisciplinary management of patients with solid malignancies. *The Oncologist*. 2019;24:e1426-e1436.
8. Gkika E, Grosu AL, Mercade TM, et al. Tumor treating fields concomitant with sorafenib in advanced hepatocellular cancer: Results of the HEPANOVA phase II study. *Cancers* 2022;14:1568